IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
7 OUT OF 10 PATIENTS ACHIEVED CLEARED (IGA 0) OR MINIMAL (IGA 1) WITH ≥2 GRADE IMPROVEMENT FROM BASELINE AT WEEK 24^1-3

DISCOVER 2: MAJOR SECONDARY ENDPOINT AT WEEK 24*

IGA 0/1

IN DISCOVER 1 AT WEEK 24 (SECONDARY ENDPOINT)

57% (47/82) of patients receiving TREMFYA® q8w had an IGA score of 0 (cleared) or 1 (minimal) and ≥2 grade reduction from baseline vs 15% (12/78) of patients receiving placebo (P<0.0001).

*Among patients with ≥3% BSA of psoriatic involvement and an IGA score ≥2 at baseline.

References: 1. Data on File. Janssen Biotech, Inc. 2. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30263):1-11. 3. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30265):1-11.

CONTRAINDICATIONS
TREMFYA^® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA^®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA^® and initiate appropriate therapy.

Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3

IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
7 OUT OF 10 PATIENTS ACHIEVED CLEARED (IGA 0) OR MINIMAL (IGA 1) WITH ≥2 GRADE IMPROVEMENT FROM BASELINE AT WEEK 24^1-3

IMPORTANT SAFETY INFORMATION

INDICATIONS

DOSAGE AND ADMINISTRATION

Do you want to continue to [extlink:external-url]?

IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)7 OUT OF 10 PATIENTS ACHIEVED CLEARED (IGA 0) OR MINIMAL (IGA 1) WITH ≥2 GRADE IMPROVEMENT FROM BASELINE AT WEEK 241-3

DOSAGE AND ADMINISTRATION

Do you want to continue to [extlink:external-url]?

IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
7 OUT OF 10 PATIENTS ACHIEVED CLEARED (IGA 0) OR MINIMAL (IGA 1) WITH ≥2 GRADE IMPROVEMENT FROM BASELINE AT WEEK 24^1-3